Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication

Clinical Science

Volumn 101, Issue 3, 2001, Pages 305-311

  Lee, T M ^a   Su, S F ^a   Tsai, C H ^a   Lee, Y T ^a   Wang, S S ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cilostazol; Intermittent claudication; Pentoxifylline; Peripheral vascular disease; Phosphodiesterase inhibitor; Vascular endothelial growth factor

Indexed keywords

CILOSTAZOL; PENTOXIFYLLINE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EXERCISE TOLERANCE; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; WALKING;

AGED; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; ENDOTHELIAL GROWTH FACTORS; EXERCISE TOLERANCE; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; LYMPHOKINES; MALE; MIDDLE AGED; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TETRAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VASODILATOR AGENTS;

EID: 0034853165     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20000281     Document Type: Article

References (37)

1. Epidemiology of atherosclerotic disease in the lower limbs
2. Conservative management of intermittent claudication
3. Cilostazol approved for use in intermittent claudication
4. Cilostazol has beneficial effects in treatment of intermittent claudication
5. Vascular endothelial growth factor is secreted angiogenic mitogen
6. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in rabbit model of chronic limb ischemia
7. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion
8. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
9. The evidence for exercise-induced inflammation in intermittent claudication: Should we encourage patients to stop walking?
10. Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia
11. Recommended standards for reports dealing with lower extremity ischemia: Revised version
12. Clinical update on pentoxifylline therapy for diabetes-induced peripheral vascular disease
13. In vitro release of vascular endothelial growth factor during platelet aggregation
14. 121 gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia
15. Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials
16. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals
17. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF
18. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide
19. Mechanisms underlying endothelial dysfunction in diabetes mellitus
20. Capillary density of skeletal muscle: A contributing mechanism for exercise intolerance in class II-III chronic heart failure independent of other peripheral alteration
21. Role of VEGF-flt receptor system in normal and tumor angiogenesis
22. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia
23. Adenosine and hypoxia stimulate proliferation and migration of endothelial cells
24. Regulation of vascular endothelial growth factor expression by cAMP in rat aortic smooth muscle cells
25. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon spicing
26. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells
27. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis
28. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells
29. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
30. Intracellular pool of vascular endothelial growth factor in human neutrophils
31. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor
32. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study
33. Beneficial hemorheological therapy of chronic peripheral arterial disorders with pentoxifylline: Results of double-blind study versus vasodilator-nylidrin
34. The rheological efficiency of parenteral pentoxifylline (Trental) in patients with ischemic brain lesions. Preliminary results
35. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb
36. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
37. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys